Beyond Air preannounces $2.3 million revenue, reaffirms 2026 and 2027 guidance
The company said LungFit PH sales rose on commercial execution gains while its second-generation system stays under FDA review.
SEC filing (2)
Latest
1 story
Sign inSign in1 story
The company said LungFit PH sales rose on commercial execution gains while its second-generation system stays under FDA review.
SEC filing (2)